NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $6.39 -0.81 (-11.25%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$6.45 +0.06 (+0.94%) As of 10/16/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Precigen Stock (NASDAQ:PGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Precigen alerts:Sign Up Key Stats Today's Range$6.31▼$7.2250-Day Range$6.10▼$8.5652-Week Range$3.04▼$8.98Volume5.49 million shsAverage Volume5.23 million shsMarket Capitalization$2.28 billionP/E RatioN/ADividend YieldN/APrice Target$13.67Consensus RatingModerate Buy Company Overview Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases, including cancer, infectious diseases and certain immune-related conditions. The company uses its proprietary technologies to engineer therapies intended to improve treatment precision, durability and accessibility. Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis, as well as programs based on its UltraCAR-T platform for cancer treatment. The company has also developed additional gene- and cell-therapy candidates using engineered viral vectors and other biologic delivery technologies. Precigen was formerly known as Intrexon Corporation and adopted its current name in 2020. The company is headquartered in Germantown, Maryland, and conducts its research and clinical-development activities primarily in the United States. Helen Sabzevari serves as Precigen’s president and chief executive officer.AI Generated. May Contain Errors. Read More Precigen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePGEN MarketRank™: 3.763349830685 of 5 starsPrecigen scored higher than 75% of companies evaluated by MarketBeat, and ranked 154th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPrecigen has a consensus price target of $13.67, representing about 113.9% upside from its current price of $6.39.Amount of Analyst CoveragePrecigen has only been the subject of 4 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth204.17% Earnings GrowthEarnings for Precigen are expected to grow by 204.17% in the coming year, from $0.24 to $0.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 106.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Precigen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.76% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 7.38.Change versus previous monthShort interest in Precigen has recently increased by 12.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentPrecigen has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Precigen this week, compared to 4 articles on an average week.Search Interest15 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows2 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have sold 11,259.61% more of their company's stock than they have bought. Specifically, they have bought $24,662.00 in company stock and sold $2,801,508.00 in company stock.Percentage Held by Insiders41.40% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PGEN Stock News HeadlinesCritical Comparison: Precigen (NASDAQ:PGEN) vs. Pyxis Oncology (NASDAQ:PYXS)October 12, 2026 | americanbankingnews.comZacks Research Downgrades Precigen (NASDAQ:PGEN) to HoldOctober 7, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | Investors Alley (Ad)PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?September 30, 2026 | finance.yahoo.comPrecigen: The FDA's Platform Technology Designation And The Institutional Crossover EffectSeptember 30, 2026 | seekingalpha.comPrecigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?September 29, 2026 | finance.yahoo.comPrecigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?September 26, 2026 | finance.yahoo.comB Riley Securities initiates coverage of Precigen at buySeptember 26, 2026 | msn.comSee More Headlines PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $4.18 at the beginning of 2026. Since then, PGEN stock has increased by 52.9% and is now trading at $6.39. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) announced its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business's revenue was up 6322.7% on a year-over-year basis. Read the conference call transcript. When did Precigen IPO? Precigen (PGEN) raised $150 million in an IPO on Tuesday, September 25th 2018. The company issued 9,999,999 shares at $14.00-$16.00 per share. Who are Precigen's major shareholders? Top institutional shareholders of Precigen include USA Financial Formulas. Insiders that own company stock include Helen Sabzevari, Donald P Lehr, Jeffrey Thomas Perez, Rutul R Shah, Nancy H Agee, Randal J Kirk, Harry Jr Thomasian and Jeffrey B Kindler. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Tesla (TSLA), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Alibaba Group (BABA), Intel (INTC), Gilead Sciences (gild) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/04/2026Today10/16/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PGEN's financial health is in the Green zone, according to TradeSmith. PGEN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PGEN CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees47Year Founded1998Price Target and Rating Average Price Target for Precigen$13.67 High Price Target$18.00 Low Price Target$11.00 Potential Upside/Downside+113.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E Ratio26.63 P/E GrowthN/ANet Income-$250.64 million Net Margins-183.98% Pretax Margin-183.98% Return on Equity423.75% Return on Assets84.39% Debt Debt-to-Equity Ratio2.15 Current Ratio4.58 Quick Ratio3.89 Sales & Book Value Annual Sales$9.68 million Price / Sales235.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book106.50Miscellaneous Outstanding Shares356,510,000Free Float208,915,000Market Cap$2.28 billion OptionableOptionable Beta0.92 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PGEN) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
